Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts
October 08 2024 - 8:03AM
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "the Company")
(Nasdaq: CPRX), a commercial-stage biopharmaceutical company
focused on in-licensing, developing, and commercializing novel
therapies for patients with rare diseases, today announced that it
has contributed $100,000 to the American Red Cross to support
ongoing relief efforts for communities impacted by Hurricane
Helene.
"At Catalyst, our commitment to the community is
unwavering, particularly in times of crisis," said Richard J. Daly,
President and CEO of Catalyst. "We extend our heartfelt sympathies
to those affected by Hurricane Helene and are honored to contribute
to the American Red Cross relief efforts. Through our donation, we
aim to help ensure that essential resources reach those who need
them most during this challenging time."
“Thanks to Catalyst Pharmaceuticals’ generous
donation, the American Red Cross, alongside our partners, is able
to support families who experienced the heartbreaking devastation
from Hurricane Helene,” said Anne McKeough, Chief Development
Officer at the American Red Cross. “We are grateful for partners
like Catalyst Pharmaceuticals as we work together to provide
comfort and hope to people when they need it most.”
Hurricane Helene has caused widespread
devastation, leading to urgent support needs for displaced
families. In response to Hurricane Helene, the American Red Cross
has mobilized a massive relief effort to bring critical aid to
those in need with help. Across the Carolinas, Tennessee, Georgia
and Florida, over 1,400 Red Cross disaster responders are working
tirelessly to provide safe shelter, meals and comfort to families
facing unimaginable destruction. Catalyst's contribution will help
sustain these vital efforts and bring hope to those in need.
For those who wish to join in supporting the
relief efforts, donations can be made directly to the American Red
Cross at https://www.redcross.org.
About Catalyst
PharmaceuticalsCatalyst Pharmaceuticals, Inc. (Nasdaq:
CPRX) is a biopharmaceutical company committed to improving the
lives of patients with rare diseases. With a proven track record of
bringing life-changing treatments to the market, we focus on
in-licensing, commercializing, and developing innovative therapies.
Guided by our deep commitment to patient care, we prioritize
accessibility, ensuring patients receive the care they need through
a comprehensive suite of support services designed to provide
seamless access and ongoing assistance. Catalyst maintains a
well-established U.S. presence while actively seeking to expand its
global commercial footprint through strategic partnerships.
Catalyst is headquartered in Coral Gables, FL., and was recognized
on the Forbes 2024 list as one of America's most successful
small-cap companies. For more information, please visit Catalyst's
website at www.catalystpharma.com.
Forward-Looking StatementsThis
press release contains forward-looking statements, as that term is
defined in the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks and
uncertainties, which may cause Catalyst's actual results in future
periods to differ materially from forecasted results. A number of
factors, including those factors described in Catalyst's Annual
Report on Form 10-K for the fiscal year 2023 and its other filings
with the U.S. Securities and Exchange Commission ("SEC"),
could adversely affect Catalyst. Copies of Catalyst's filings with
the SEC are available from the SEC, may be found on
Catalyst's website, or may be obtained upon request from Catalyst.
Catalyst does not undertake any obligation to update the
information contained herein, which speaks only as of this
date.
Source: Catalyst Pharmaceuticals, Inc.
Investor Contact
Mary Coleman, Catalyst Pharmaceuticals, Inc.
(305) 420-3200
mcoleman@catalystpharma.com
Media Contact
David Schull, Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Oct 2023 to Oct 2024